Neurogene Inc (NGNE)
40.67
+4.25
(+11.67%)
USD |
NASDAQ |
Jul 01, 16:00
40.59
-0.08
(-0.20%)
After-Hours: 20:00
Neurogene Enterprise Value: 322.60M for June 28, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 28, 2024 | 322.60M |
| June 27, 2024 | 301.83M |
| June 26, 2024 | 265.36M |
| June 25, 2024 | 253.55M |
| June 24, 2024 | 261.98M |
| June 21, 2024 | 252.38M |
| June 20, 2024 | 253.16M |
| June 18, 2024 | 243.42M |
| June 17, 2024 | 369.07M |
| June 14, 2024 | 402.69M |
| June 13, 2024 | 394.90M |
| June 12, 2024 | 332.47M |
| June 11, 2024 | 332.47M |
| June 10, 2024 | 334.67M |
| June 07, 2024 | 341.55M |
| June 06, 2024 | 332.21M |
| June 05, 2024 | 336.23M |
| June 04, 2024 | 339.61M |
| June 03, 2024 | 333.12M |
| May 31, 2024 | 337.92M |
| May 30, 2024 | 291.58M |
| May 29, 2024 | 282.62M |
| May 28, 2024 | 261.47M |
| May 24, 2024 | 266.66M |
| May 23, 2024 | 258.61M |
| Date | Value |
|---|---|
| May 22, 2024 | 270.42M |
| May 21, 2024 | 271.98M |
| May 20, 2024 | 291.32M |
| May 17, 2024 | 282.23M |
| May 16, 2024 | 287.56M |
| May 15, 2024 | 285.87M |
| May 14, 2024 | 259.39M |
| May 13, 2024 | 247.58M |
| May 10, 2024 | 271.72M |
| May 09, 2024 | 280.94M |
| May 08, 2024 | 276.91M |
| May 07, 2024 | 290.41M |
| May 06, 2024 | 275.74M |
| May 03, 2024 | 321.13M |
| May 02, 2024 | 305.18M |
| May 01, 2024 | 284.33M |
| April 30, 2024 | 293.47M |
| April 29, 2024 | 279.57M |
| April 26, 2024 | 235.32M |
| April 25, 2024 | 234.16M |
| April 24, 2024 | 238.79M |
| April 23, 2024 | 250.88M |
| April 22, 2024 | 243.68M |
| April 19, 2024 | 242.14M |
| April 18, 2024 | 256.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
137.17M
Minimum
Dec 20 2023
608.65M
Maximum
Mar 28 2024
332.68M
Average
336.58M
Median
Feb 20 2024
Enterprise Value Benchmarks
| Taysha Gene Therapies Inc | 331.71M |
| CEL-SCI Corp | 57.52M |
| AIM ImmunoTech Inc | 11.43M |
| IGC Pharma Inc | 31.75M |
| NovaBay Pharmaceuticals Inc | 3.058M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.92M |
| Total Expenses (Quarterly) | 18.78M |
| EPS Diluted (Quarterly) | -1.00 |
| Earnings Yield | -66.95% |